amycretin vs semaglutide

NCT06064006 · Phase 2 · completed

The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.

NCT03548935 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.

NCT06542874 · Phase 2 · completed

This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).